Digital health care company Voluntis revealed on Thursday the receipt of US FDA's clearance and the CE mark to integrate Basaglar and Tresiba.

In conjunction, Insulia, its digital companion for people with Type 2 diabetes, now cleared for titration of all brands of basal insulin, added the company.

Following the US FDA approval, Insulia is now available for people using any brand of basal insulin including Lantus, Levemir, Toujeo, Tresiba and Basaglar.

Additionally, the company will continue to work to make Insulia available to those using other insulin therapies, including NPH insulin and GLP-1/basal insulin combinations, aiming for release in 2018. Insulia is currently available for patients throughout the US via prescription from their provider.

The Insulia app, which is available on iOS and Android devices, is now paired with web portal for healthcare practitioners.

According to the company, Insulia is an automated, prescription-only digital companion for people with type 2 diabetes and their care teams that helps people get to the right dose, every day. It combines a patient mobile app and health care practitioner (HCP) web portal. The mobile app provides real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose values. It is then available for download on the App Store and Google Play.